

Experiment Number: K93025B

Route: Whole Body Inhalation

Species/Strain: Rats/F344/N

Toxicokinetics Data Summary

Compound: Tetralin/ Analyte: Tetralin

CAS Number: 119-64-2

Request Date: 7/11/2023

Request Time: 10:03:16

Lab: Battelle Northwest

Male

Treatment Group (ppm)

15 Inhalation Plasma<sup>a</sup>

60 Inhalation Plasma<sup>a</sup>

120 Inhalation Plasma<sup>a</sup>

	15 Inhalation Plasma <sup>a</sup>	60 Inhalation Plasma <sup>a</sup>	120 Inhalation Plasma <sup>a</sup>
C <sub>0</sub> min <sub>pred</sub> (ug/mL)	0.330 ± 0.019	1.68 ± 0.13	4.58 ± 0.47
Alpha (minute <sup>-1</sup> )	0.0314 ± 0.0063	0.0257 ± 0.0054	0.0238 ± 0.0061
Alpha Half-life (minute)	22.1 ± 4.4	27.0 ± 5.7	29.1 ± 7.5
Beta (minute <sup>-1</sup> )	0.00518 ± 0.00092	0.0317 ± 0.0010	0.00279 ± 0.0014
Beta Half-life (minute)	134 ± 24	219 ± 69	249 ± 130
AUC <sub>inf_pred</sub> (ug*min*g <sup>-1</sup> )	27.7 ± 0.69	156 ± 7.9	431 ± 26

Experiment Number: K93025B

Route: Whole Body Inhalation

Species/Strain: Rats/F344/N

Toxicokinetics Data Summary

Compound: Tetralin/ Analyte: Tetralin

CAS Number: 119-64-2

Request Date: 7/11/2023

Request Time: 10:03:16

Lab: Battelle Northwest

Female

Treatment Group (ppm)

15 Inhalation Plasma<sup>a</sup>

60 Inhalation Plasma<sup>a</sup>

120 Inhalation Plasma<sup>a</sup>

	15 Inhalation Plasma <sup>a</sup>	60 Inhalation Plasma <sup>a</sup>	120 Inhalation Plasma <sup>a</sup>
C <sub>0</sub> min <sub>pred</sub> (ug/mL)	0.278 ± 0.025	1.65 ± 0.19	4.43 ± 0.40
Alpha (minute <sup>-1</sup> )	0.0445 ± 0.015	0.0534 ± 0.016	0.0418 ± 0.011
Alpha Half-life (minute)	15.6 ± 5.1	13.0 ± 3.9	16.6 ± 4.4
Beta (minute <sup>-1</sup> )	0.00592 ± 0.0012	0.00434 ± 0.00099	0.00410 ± 0.00095
Beta Half-life (minute)	117 ± 23	160 ± 37	169 ± 39
AUC <sub>inf_pred</sub> (ug*min*g <sup>-1</sup> )	20.7 ± 1.0	127 ± 7.3	369 ± 15

**Experiment Number:** K93025B

**Route:** Whole Body Inhalation

**Species/Strain:** Rats/F344/N

**Toxicokinetics Data Summary**

**Compound:** Tetralin/**Analyte:** Tetralin

**CAS Number:** 119-64-2

**Request Date:** 7/11/2023

**Request Time:** 10:03:16

**Lab:** Battelle Northwest

---

## LEGEND

---

### MODELING SOFTWARE

SAS PROC NUN (SAS Institute Inc., Cary, NC)

### MODELING METHOD & BEST FIT MODEL

<sup>a</sup> The nonlinear least-squares fitting program used is SAS PROC NUN (SAS Institute Inc., Cary, NC). bi-exponential elimination model using a nonlinear least-squares fitting program. The toxicokinetic parameter estimates and fitted models reported were derived using a weighting scheme of 1/mean Tetralin concentration.

### ANALYTE

Tetralin

### TK PARAMETERS (All parameters use Confidence Interval instead of SD or SEM)

C<sub>0min\_pred</sub> = Fitted plasma concentration at time zero (IV only)

Alpha = Hybrid rate constant of the alpha phase

Alpha Half-life = Half-life for the alpha phase

Beta = Hybrid rate constant of the beta phase

Beta Half-Life = Half-life for the beta phase

AUC<sub>inf\_pred</sub> = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

**Experiment Number:** K93025B  
**Route:** Whole Body Inhalation  
**Species/Strain:** Rats/F344/N

**Toxicokinetics Data Summary**  
**Compound:** Tetralin/ **Analyte:** Tetralin  
**CAS Number:** 119-64-2

**Request Date:** 7/11/2023  
**Request Time:** 10:03:16  
**Lab:** Battelle Northwest

---

## TK PARAMETERS PROTOCOL

### ANALYSIS METHOD

Toxicokinetic parameters were determined by fitting the Equation  $C(t) = Aoe^{-\alpha t} + Boe^{-\beta t}$  to the data using a nonlinear least-squares fitting program where  $C(t)$  is the blood concentration of Tetralin at any postexposure time ( $t$ ),  $\alpha$  and  $\beta$  are the hybrid rate constants ( $\text{min}^{-1}$ ) obtained from the fit and  $Ao$  and  $Bo$  are the intercepts on the ordinate (concentration) axis of the extrapolated initial and terminal phases, respectively. Estimates for the toxicokinetic values, with their approximate 95% confidence intervals, were obtained directly from the model. The elimination half-lives for the initial and terminal phases of the concentration versus time profiles were calculated as  $\ln 2/\alpha$  or  $\ln 2/\beta$ , respectively. The maximum blood concentration ( $Co$ ) was assumed to occur at  $t$  equals 0 and was calculated as  $Ao + Bo$ . The area under the curve (AUC) was estimated using the trapezoidal rule from the first to the last time point (AUC<sub>t</sub>). The AUC extrapolated to infinity (AUC<sub>inf</sub>) was estimated using the equation  $AUC_{inf} = AUC_t + C_f / \beta$  where  $C_f$  is the concentration ug Tetralin/g blood measure at the final time point and  $\beta$  is the rate constant for the terminal elimination phase.

## TK\_WHOLE BODY INHALATION PLASMA

### 15 ppm Male and Female

Blood was sampled at less than 5, and 30, 45, 60, 120, 240, 360, and 480 minutes postexposure of a single 6-hour whole body inhalation exposure. Each animal was bled twice, once from each eye. The GC/MS method incorporating selected ion monitoring validated range was 0.00578 to 12.1 ug Tetralin/g blood. The limit of detection (LOD), limit of quantitation (LOQ), and experimental limit of quantitation (ELOQ) were 0.00059, 0.002, and 0.0058 ug Tetralin/g blood, respectively.

### 60 ppm, 120 ppm Male and Female

Blood was sampled at less than 5, and 30, 60, 90, 120, 240, 480, and 720 minutes postexposure. Each animal was bled twice, once from each eye. The GC/MS method incorporating selected ion monitoring validated range was 0.00578 to 12.1 ug Tetralin/g blood. The limit of detection (LOD), limit of quantitation (LOQ), and experimental limit of quantitation (ELOQ) were 0.00059, 0.002, and 0.0058 ug Tetralin/g blood, respectively.